COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
Ivermectin study #30 of 63
11/14 Late treatment study
Spoorthi et al., IAIM, 2020, 7:10, 177-182 (Peer Reviewed)
Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV-2
Source   PDF   Share   Tweet
100 patient prospective trial of ivermectin + doxycycline showing reduced time to symptom resolution and shorter hospital stay with treatment.

Spoorthi et al., 11/14/2020, prospective, India, South Asia, peer-reviewed, 2 authors, dosage not specified.
recovery time, 21.1% lower, relative time 0.79, p = 0.03, treatment 50, control 50.
hospitalization time, 15.5% lower, relative time 0.84, p = 0.01, treatment 50, control 50.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 63 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit